Post-exertional malaise (PEM) is one of the most disabling and defining features of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). For many patients, even small amounts of physical, cognitive, or emotional exertion can lead to a delayed worsening of symptoms, often appearing 12 to 48 hours later and lasting days, weeks, or longer.

PEM is not simply feeling tired after an activity. It reflects a complex, multisystem response involving immune, neurologic, autonomic, and metabolic dysfunction. Because of this complexity, management often includes pacing, environmental modification, and in some cases, medications selected based on a patient’s clinical presentation.

Below are three medications commonly used in clinical practice to address mechanisms that may contribute to PEM in some people with ME/CFS. These medications may help decrease the amount of PEM crashes people experience and/or reduce the severity of those crashes. They are not curative, and responses vary, but research and patient-reported outcomes suggest potential benefit for selected individuals under medical supervision. 

Post-exertional malaise refers to a worsening of symptoms following exertion that would not have caused problems before illness onset. Triggers can include physical activity, cognitive effort, emotional stress, or sensory overload such as bright light or sound.

Symptoms typically intensify hours to days after the trigger and may include profound fatigue, cognitive dysfunction, pain, flu-like symptoms, sleep disturbance, and autonomic instability. Recovery is often prolonged and unpredictable.

This delayed response is a defining feature of ME/CFS and is also commonly reported in Long COVID.

What it may help with:
Cognitive fatigue, physical fatigue, and PEM symptoms

How it works:
At low doses, naltrexone appears to influence neuroinflammatory and immune signaling pathways rather than functioning as an opioid antagonist. This mechanism is thought to contribute to symptom reduction in some patients.

Research overview:
A Stanford-led observational study analyzed 59 patients with Long COVID treated with low-dose naltrexone. Treatment was associated with improvements in self-reported fatigue, post-exertional malaise, unrefreshing sleep, sleep patterns, and overall functional status. No serious adverse reactions were reported.

Low-dose naltrexone is commonly prescribed off-label in ME/CFS and Long COVID due to its safety profile and reported symptom improvements in clinical settings.

What it may help with:
Exertional capacity, tolerance for activity, and symptoms related to postural orthostatic tachycardia syndrome (POTS) or orthostatic hypotension (OH)

How it works:
Pyridostigmine increases acetylcholine availability, enhancing communication between nerves and muscles. It may also improve cardiovascular filling pressures, supporting more effective blood flow during exertion.

Research overview:
Pyridostigmine has been shown to improve peak oxygen consumption by increasing cardiac output and filling pressures. These findings suggest that neurovascular dysregulation may be a contributing factor to exertional intolerance in ME/CFS.

What it may help with:
Exertional intolerance, PEM and other symptoms related to an excessive rise in heart with upright posture or activity associated with conditions like POTS or inappropriate sinus tachycardia (IST)

How it works:
Ivabradine selectively lowers heart rate by inhibiting the sinoatrial node’s “funny” channel without reducing blood pressure. Lowering both resting and activity-related heart rate may reduce physiologic strain associated with upright posture and activity, leading to reduced PEM episodes.

Research overview:
A double-blind, placebo-controlled trial involving 22 patients with hyperadrenergic POTS demonstrated significant heart rate reduction, improved quality of life, and a trend toward lower plasma norepinephrine levels.

These findings support ivabradine’s use in carefully selected patients with autonomic dysfunction.

PEM is a core symptom of ME/CFS and Long COVID, but its underlying drivers can differ between individuals. Medications such as low-dose naltrexone, pyridostigmine, and ivabradine address distinct physiologic mechanisms, including immune overactivity, neurovascular dysregulation, and autonomic dysfunction.

When used, these medications are part of a broader clinical plan that also includes pacing, symptom monitoring, and supportive care.

More information about the services and support Dr Curtin offers at her clinic can be found at: https://rthm.com

This article is for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional.

• Perrin Technique: toxins & the nervous system
• Naturopath: 5 things I recommend to my CFS clients
• Mitochondrial failure: the cause of CFS symptoms?